Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.41 |
| ▸ | ITGB2 | P05107 | 2/20 | 0.39 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.39 |
| ▸ | ITGAL | P20701 | 2/20 | 0.39 |
| ▸ | PYGL | P06737 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11306763 | 1.00 | ALDH1A1 (0.46) | ALDH1A1KMT2AMAPTMEN1USP2 | |
| SCHEMBL679130 | 1.00 | ALDH1A1 (0.46) | ALDH1A1KMT2AMAPTMEN1USP2 | |
| SCHEMBL5175942 | 0.90 | ALDH1A1 (0.56) | ALDH1A1KMT2ATAAR1 | |
| SCHEMBL3676837 | 0.90 | ALDH1A1 (0.56) | ALDH1A1KMT2ATAAR1 | |
| SCHEMBL3676840 | 0.90 | ALDH1A1 (0.56) | ALDH1A1KMT2ATAAR1 | |
| SCHEMBL8894733 | 0.89 | CNR2 (0.51) | ALDH1A1KMT2AMAPTMEN1USP2 | |
| SCHEMBL8897538 | 0.89 | CNR2 (0.51) | ALDH1A1KMT2AMAPTMEN1USP2 | |
| SCHEMBL25381181 | 0.88 | ALDH1A1 (0.42) | ALDH1A1KMT2AMAPTMEN1USP2 | |
| SCHEMBL5055232 | 0.88 | ALDH1A1 (0.38) | ALDH1A1KMT2AMAPTMEN1USP2 | |
| SCHEMBL5175940 | 0.88 | ALDH1A1 (0.38) | ALDH1A1KMT2AMAPTMEN1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070270496-A1 | Pharmaceutical composition for the treatment of pathologies caused by the general response of the immune system | EPITECH GROUP S.R.L. (IT) | 2007-11-22 | — | — | US | claimed |
| EP-1844784-A1 | A pharmaceutical composition for the treatment of pathologies caused by the general response of the immune system | Epitech Group S.r.l. (IT) | 2007-10-17 | — | — | EP | claimed |
| US-20110288037-A1 | Pharmaceutical Composition for the Treatment of Pathologies Caused by the General Response of the Immune System | DELLA VALLE FRANCESCO (IT) | 2011-11-24 | — | — | US | disclosed |
| US-20110146516-A1 | METHOD OF PREPARING LITHOGRAPHIC PRINTING PLATE | FUJIFILM CORPORATION (JP) | 2011-06-23 | — | — | US | disclosed |
| US-20110017084-A1 | IMMERSION TYPE AUTOMATIC DEVELOPING APPARATUS FOR LITHOGRAPHIC PRINTING PLATE AND AUTOMATIC DEVELOPING METHOD | FUJIFILM CORPORATION (JP) | 2011-01-27 | — | — | US | disclosed |
| US-20110020757-A1 | METHOD OF PREPARING LITHOGRAPHIC PRINTING PLATE | FUJIFILM CORPORATION (JP) | 2011-01-27 | — | — | US | disclosed |
| US-20070270496-A1 | Pharmaceutical composition for the treatment of pathologies caused by the general response of the immune system | EPITECH GROUP S.R.L. (IT) | 2007-11-22 | — | — | US | disclosed |
| EP-1844784-A1 | A pharmaceutical composition for the treatment of pathologies caused by the general response of the immune system | Epitech Group S.r.l. (IT) | 2007-10-17 | — | — | EP | disclosed |
| US-5925678-A | ADMINISTERING N,N*-BIS-(2-HYDROXYETHYL)-NONANDIAMIDE | LIFEGROUP S.P.A. (IT) | 1999-07-20 | — | — | US | disclosed |
| EP-0804179-B1 | USE OF N-ACYL DERIVATIVES OF AMINOALCOHOLS IN THE MANUFACTURE OF A MEDICAMENT FOR PRACTISING NEUROPROTECTIVE ACTION IN NEUROPATHOLOGICAL STATES CONNECTED WITH EXCITOTOXICITY | LIFEGROUP SPA (IT) | 1999-07-14 | — | — | EP | disclosed |
| US-5618842-A | TREATING DERMATOLOGIC, OPTHALMIC, MUCOSAL, ARTICULAR, CONNECTIVE TISSUE, NERVOUS SYSTEM, ALLERGIC, INFLAMMATORY PATHOLOGIES | LIFEGROUP S.P.A. (IT) | 1997-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288037-A1 | Pharmaceutical Composition for the Treatment of Pathologies Caused by the General Response of the Immune System | HCAR2, HCAR1, MYD88 | ALDH1A1 824/4885KMT2A 3832/4885MAPT 1479/4885 |
| US-20070270496-A1 | Pharmaceutical composition for the treatment of pathologies caused by the general response of the immune system | HCAR2, HCAR1, MYD88 | ALDH1A1 824/4885KMT2A 3832/4885MAPT 1479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.